Back to Search
Start Over
Design and rationale of FLAVOUR: A phase IIa efficacy study of the 5-lipoxygenase activating protein antagonist AZD5718 in patients with recent myocardial infarction
- Source :
- Contemporary Clinical Trials Communications; September 2020, Vol. 19 Issue: 1
- Publication Year :
- 2020
-
Abstract
- Patients with coronary artery disease remain at increased risk of recurrent life-threatening cardiovascular events even after adequate guideline-based treatment of conventional risk factors, including blood lipid levels. Inflammation is a critical pathway in the pathogenesis of atherosclerosis and is independently associated with risk of recurrent cardiovascular events. Leukotrienes are potent pro-inflammatory and vasoactive mediators synthesized by leukocytes in atherosclerotic lesions. AZD5718 is a novel antagonist of 5-lipoxygenase activating protein that suppresses leukotriene biosynthesis.
Details
- Language :
- English
- ISSN :
- 24518654
- Volume :
- 19
- Issue :
- 1
- Database :
- Supplemental Index
- Journal :
- Contemporary Clinical Trials Communications
- Publication Type :
- Periodical
- Accession number :
- ejs53927738
- Full Text :
- https://doi.org/10.1016/j.conctc.2020.100629